Population-Based Assessment of Determining Treatments for Prostate Cancer.

Many men with indolent prostate cancer often opt for radical prostatectomy or radiotherapy treatment for their disease. These men may experience considerable detriments of quality of life owing to sexual, urinary, and/or rectal toxic effects associated with these treatments.

Without a better understanding of the mutable agents and predictors of treatment types, diffusion of expectant management among these men will be slow.

To determine population-based predictors for treatment and use of watchful waiting or active surveillance for indolent prostate cancer.

We used Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data. A total of 37 621 men in the general community diagnosed as having prostate cancer from 2004 to 2007 were followed until December 31, 2009.

Watchful waiting or active surveillance, radiation therapy, or radical prostatectomy.

We used mixed-effects logistic regression analysis to determine the factors associated with aggressive treatment and use of watchful waiting or active surveillance for men with prostate cancer.

The most common treatment type is radiation therapy (57. 9% [95% CI, 57. 4%-58. 4%]), followed by radical prostatectomy (19. 1% [95% CI, 18. 7%-19. 5%]) and watchful waiting or active surveillance (9. 6% [95% CI, 9. 3%-9. 9%]). Moreover, patients and providers significantly integrate age (odds ratio [OR], 0. 32 [95% CI, 0. 29-0. 35]) and comorbidities (OR, 0. 62 [95% CI, 0. 56-0. 68]) when determining radical prostatectomy, while regional variation (OR, 0. 57 [95% CI, 0. 47-0. 68]) and referral patterns (OR, 44. 46 [95% CI, 41. 04-48. 17]) influence the use of radiation therapy. Patient demographics and tumor characteristics significantly account for 40% of patients undergoing prostatectomy, 12% choosing watchful waiting or active surveillance, and only 3% undergoing radiotherapy.

There is increased use of radiotherapy among patients with indolent prostate cancer with limited to no correlation with tumor biology. Active surveillance was underused, and a significant proportion of the variance was unexplained. Further research into qualitatively describing the contributing factors that drive decision-making recommendations for prostate cancer patients is needed.

JAMA oncology. 2015 Apr 01 [Epub]

Karim Chamie, Stephen B Williams, Jim C Hu

Department of Urology, David Geffen School of Medicine at University of California, Los Angeles. , Department of Urology, The University of Texas MD Anderson Cancer Center, Houston. , Department of Urology, David Geffen School of Medicine at University of California, Los Angeles.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe